EUVIMEDEUVIMED entdecken
Crossref

Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment

Cunbo Ma iD, Di Kang iD, Panliang Gao iD, Wei Zhang iD, Xinping Wu iD, Zilong Xu iD, Huifeng Han iD, Lei Zhang iD, Yang Cai iD, Yanping Wang iD, Yinxiang Wang iD, Wei Long iD

Journal of Medicinal Chemistry · 22.08.2024 · 67 (16) · 13534-13549

DOI: 10.1021/acs.jmedchem.4c00360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.08.2024. Verfasst von Cunbo Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Jacobio Pharmaceuticals, Beijing 101111, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As an oncogenic phosphatase, SHP2 acts as a converging node in the RTK-RAS-MAPK signaling pathway in cancer cells and suppresses antitumor immunity by passing signals downstream of PD-1. Here, we utilized the extra druggable pocket outside the previously identified SHP2 allosteric tunnel site by the (6,5 fused), 6 spirocyclic system. The optimized compound, JAB-3312, exhibited a SHP2 binding Kd of 0.37 nM, SHP2 enzymatic IC50 of 1.9 nM, KYSE-520 antiproliferative IC50 of 7.4 nM and p-ERK inhibitory IC50 of 0.23 nM. For JAB-3312, an oral dose of 1.0 mg/kg QD was sufficient to achieve 95% TGI in KYSE-520 xenograft model of mouse. JAB-3312 was well-tolerated in animal models, and a close correlation was observed between the plasma concentration of JAB-3312 and the p-ERK inhibition in tumors. Currently, JAB-3312 is undergoing clinical trials as a potential anticancer agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsHumansAnimalsMiceAllosteric RegulationCell Line, TumorStructure-Activity RelationshipXenograft Model Antitumor AssaysCell ProliferationDrug DiscoveryEnzyme InhibitorsMice, NudeFemaleNeoplasms

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsEnzyme InhibitorsPTPN11 protein, human

Autor:innen und Institutionen

  • Medicinal Chemistry, Jacobio Pharmaceuticals, Beijing 101111, China.
  • Pharmacology, Jacobio Pharmaceuticals, Beijing 101111, China.
  • Hits Discovery, Jacobio Pharmaceuticals, Beijing 101111, China.

ORCID-Profile: Cunbo Ma, Di Kang, Panliang Gao, Wei Zhang, Xinping Wu, Zilong Xu, Huifeng Han, Lei Zhang, Yang Cai, Yanping Wang, Yinxiang Wang, Wei Long

Zitieren

APA

Ma, C., Kang, D., Gao, P., Zhang, W., Wu, X., Xu, Z., Han, H., Zhang, L., Cai, Y., Wang, Y., Wang, Y., & Long, W. (2024). Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. Journal of Medicinal Chemistry, 67(16), 13534-13549. https://doi.org/10.1021/acs.jmedchem.4c00360

Vancouver

Ma C, Kang D, Gao P, Zhang W, Wu X, Xu Z, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. Journal of Medicinal Chemistry. 2024;67(16):13534-13549. doi:10.1021/acs.jmedchem.4c00360

BibTeX
@article{Ma2024,
  author = {Ma, Cunbo and Kang, Di and Gao, Panliang and Zhang, Wei and Wu, Xinping and Xu, Zilong and Han, Huifeng and Zhang, Lei and Cai, Yang and Wang, Yanping and Wang, Yinxiang and Long, Wei},
  title = {Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {16},
  pages = {13534--13549},
  doi = {10.1021/acs.jmedchem.4c00360}
}
Kostenlos starten →